Underweight ABT: Trim 40-45% at $116 into overbought stretch (RSI 75.43, 15.2% above 50 SMA) with 55-60% core retained for Dividend King compounding
Underweight rating is warranted given the stretched setup exceeds the 8/18 setup ($112.68, RSI 73.20, 14.8% above 50 SMA) when Underweight captured +1.3% alpha, with today's $116.13 at RSI 75.43 and 15.2% above the 50 SMA creating textbook exhaustion geometry. The 40-45% trim captures alpha opportunity in overbought conditions while maintaining 55-60% core conviction for Dividend King compounding — a coherent middle ground between too-timid 30% trim and too-aggressive 60%+ trim that would imply structural thesis break inconsistent with the Dividend Aristocrat's intact floor ($7B FCF, $670M NEC litigation resolved, golden cross forming).
| Position | Action |
|---|---|
| Current position at ~$116 with RSI 75.43, 15.2% above 50 SMA, MACD histogram compressed at +0.21 against new highs | Trim 40-45% of ABT exposure via 2-3 tranches over 1-2 weeks |
| Price pulls back to $102-105 (rising 50 SMA convergence zone) | Reload ~55% of trim capital |
| Price reaches $95-98 (deep-value insurance zone) | Reload ~45% of trim capital as macro sell-off insurance |
| Daily close below $105.81 on rising volume | 200 SMA structural break — triggers Sell downgrade |
| Q3 integration commentary disappoints | Tighten trailing stop to $108 close |
| Price pushes above $117 before Sep 16 FOMC | Trim additional 10-15% into strength |
Abbott Laboratories is undergoing a fundamental rerating driven by litigation overhang elimination, new CGM growth catalysts, and favorable macro conditions for defensive dividend compounders.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 113.59 | bullish |
| close_50_sma | 100.78 | bullish |
| close_200_sma | 105.81 | bullish |
| rsi | 75.43 | bearish |
| boll_middle | 110.31 | neutral |
| boll_ub | 117.88 | bearish |
| atr | 2.50 | neutral |
| vwma | 111.75 | bullish |
| macd | 4.32 | bullish |
| macd_signal | 4.12 | bullish |
| macd_histogram | 0.21 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Reload ~55% of trim capital
New CGM growth channels are live and expanding Abbott's dominance beyond direct-to-consumer Libre
↩ rebuts: “Bear label of ABT as 'boring healthcare'”
· concedes: RSI at 75.43 is technically overbought; Debt-to-equity jumped significantly from ~26% to 63%; Q1 2026 EPS collapsed to $0.53 due to integration costs; Price pressing against Bollinger upper band at $117.88
Abbott's 41.7% rally is a relief bounce on a fragile fundamental picture—the $20B undisclosed acquisition, $670M NEC settlement, and overbought technicals create asymmetric downside risk at $116.13.
EV: -$5 to -$10 per share (asymmetric downside to $102-$110 or $95-$98 from current $116.13) · concedes: NEC settlement provides some near-term cash certainty, even if not a clean legal exit; Technical indicators can remain elevated for extended periods during strong trends; Historical M&A issues (Alere) do not guarantee future poor outcomes; FreeStyle Libre franchise is genuinely strong and established; Dividend King status provides some floor support
→ vs conservative: Defending Dividend King at 19.15x forward P/E premium to sector is paying elevated multiple for a stock that dropped from $134 to $81 in 8 months; $20B acquisition with unproven integration and $35B goodwill represents $20B bet on unnamed target
→ vs neutral: 'Constructive on pullbacks, cautious at highs' is the exact logic for trimming now; saying you'd add at $110 while holding full size at $116 is paying extra for the same position
Support: 113.59 · 112.68 · 110.31 · 107 · 100.78 | Resistance: 117.34 · 117.88
ABT is in a powerful short-term uptrend with price above all three major moving averages (10 EMA, 50 SMA, 200 SMA) and higher highs/lows intact since the 07-16 gap-up reversal. However, multiple caution flags suggest the rally is extended: RSI at 75.43 (overbought), price only 1.5% below the upper Bollinger Band at $117.88, and ~15% extension above the 50 SMA. Key resistance sits at $117.34–$117.88; critical support at $113.59 (10 EMA) and $110.31 (Bollinger midline), with deeper support at $100.78 (50 SMA). ATR of $2.50 (~2.2% of price) indicates orderly volatility suitable for 1–2× ATR stop placement. VWMA confirms accumulation is supporting the rally. The verdict recommends waiting for pullbacks to $110–$113 for better risk/reward on new positions.
Market Cap
$200.95B
P/E (TTM)
37.58
Forward P/E
19.15
PEG Ratio
2.35
P/B
3.93
Dividend Yield
2.16%
52-Week High
$137.49
52-Week Low
$81.97
50-Day MA
$100.48
200-Day MA
$107.04
Beta
0.581
Revenue (TTM)
$46.58B
Gross Profit (TTM)
$26.48B
EBITDA (TTM)
$11.68B
Net Income (TTM)
$5.40B
Gross Margin
56.8%
Operating Margin
14.71%
Net Profit Margin
11.65%
ROE
10.58%
ROA
5.33%
EPS (TTM)
$3.09
Forward EPS
$6.06
Book Value/Share
$29.54
Total Debt
$34.05B
Cash & Equivalents
$6.80B
Net Debt
$27.24B
Goodwill
$35.22B
Other Intangibles
$17.88B
Stockholders' Equity
$52.06B
Current Ratio
1.376
Debt-to-Equity
63.2%
Working Capital
$7.13B
Free Cash Flow (TTM)
$7.21B
Annual Dividends Paid (2025)
$4.12B
CapEx (2025)
$2.17B
Q1 2026 Acquisition Amount
$19.80B
Q1 2026 New Debt Issued
$19.86B
Q1 2026 Diluted EPS
$0.53
Q1 2026 Operating Income
$1.345B
R&D Spend (Quarterly)
$0.72B–$0.77B
Strengths
Concerns
Abbott Laboratories presents a classic earnings reset opportunity: a high-quality defensive healthcare franchise trading ~27% below its 52-week high with forward P/E of just 19.15x, but obscured by near-term integration drag from a ~$20B acquisition that drove debt-to-equity from ~26% to 63%. The company's $46.6B revenue scale, FreeStyle Libre CGM dominance, and robust FCF generation ($7.21B TTM) provide fundamental durability, while the 2.16% dividend yield and Dividend Aristocrat status offer income support. The critical variable is the unidentified $19.8B acquisition target—traders should monitor Q2 2026 earnings (mid-July) for the first signs of synergy realization and integration progress, which will determine whether the forward EPS consensus of $6.06 materializes within the expected timeframe.